Political appointee stalls Sanofi drug approval, raising concerns about FDA interference

STAT's D.C. Diagnosis newsletter reports that a political appointee is impeding the approval of a Sanofi drug, suggesting direct political interference at the FDA.

The article notes that the appointee's actions are slowing the review process, without providing specific details about the drug or timeline, and frames this as part of a broader pattern of political influence on regulatory decisions.

Analysts and industry observers see such interference as a risk to drug development timelines, potentially delaying patient access and affecting investor confidence in the regulatory environment.

The piece underscores growing concerns among pharma professionals about the independence of the FDA and the impact of political appointments on critical approval pathways.